A single-center phase I study in healthy, male volunteers, consisting of two separate randomized, double-blind, placebo controlled three-period cross-over sessions assessing the effect of NXY-059 (8 h i.v. infusion) on bleeding time, platelet aggregation and platelet adhesion as compared with that of desmopressin (10 min i.v. injection) and ASA (160 mg o.d. for three days) respectively

Study identifier:SA-NXY-0008

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A single-center phase I study in healthy, male volunteers, consisting of two separate randomized, double-blind, placebo controlled three-period cross-over sessions assessing the effect of NXY-059 (8 h i.v. infusion) on bleeding time, platelet aggregation and platelet adhesion as compared with that of desmopressin (10 min i.v. injection) and ASA (160 mg o.d. for three days) respectively

Medical condition

Stroke

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Oct 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

-

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria